TNF-alpha blockade induce clinical remission in patients affected by polymyalgia rheumatica associated to diabetes mellitus and/or osteoporosis: A seven cases report

European Review for Medical and Pharmacological Sciences

Volumn 9, Issue 6, 2005, Pages 373-378

  Migliore, A ^a   Massafra, U ^a   Carloni, E ^a   Padalino, C ^a   Martin Martin, S ^b   Lasaracina, F ^a   Dibiase, N ^a   Alimonti, A ^a   Granata, M ^c  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b REGINA APOSTOLORUM HOSPITAL   (Italy)

^c SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

Corticosteroid treatment; Diabetes mellitus; Infliximab; Osteoporosis; Polymyalgia reumatica; TNF alpha blockade

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; INFLIXIMAB; INSULIN; METHOTREXATE; ORAL ANTIDIABETIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; OSTEOPOROSIS; PHYSICAL EXAMINATION; RECEPTOR BLOCKING; REMISSION; RHEUMATIC POLYMYALGIA; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; OSTEOPOROSIS; POLYMYALGIA RHEUMATICA; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 31844455558     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Salvarani C, Gabriel SE, Hunder GG. Epidemiology of polymyalgia rheumatica in Omsted Country, Minnesota 1970-1991. Arthritis Rheum 1995: 38: 369-373.
2. Salvarani C, Macchioni PL, Zizzi F, et al. Epidemiology and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum 1991; 34: 351-356.
3. The Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2000. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2002.
4. Melton U. How many have osteoporosis now? J Bone Miner Res 1995; 10: 175-177.
5. Bruce W. Senile Rheumatic gout. Br Med J 1888; 2: 811-813.
6. Chuang T-Y, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-years epidemiological and clinical study. Ann Intern Med 1982; 97: 672-680.
7. Healy LA. Long term follow up of polymyalgia rheumatica: evidence for synovitis. Semin Arthrit Rheumatol 1984; 13: 322-328.
8. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatolgy 1990 criteria for the classification of giant cell artertis. Arthritis Rheum 1990; 33: 1122-1128.
9. Salvarani C, Cantini F, Boiardi MD, Hunder GG. Polymyalgia rheumatica and giant-cell Arteritis. N Engl J Med 2002; 347: 261-271.
10. Andersson R, Malmavall B-E, Bengsson B-A. Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand 1986: 220: 465-469.
11. Salvarani C, Macchioni L, Boiardi L. Polymyalgia rheumatica. Lancet 1997; 350: 43-47.
12. Chantler IW, Davie MW, Evans SF, Rees JS. Oral corticosteroid prescribing in women over 50, use of fracture prevention therapy, and bone densitometry service. Ann Rheum Dis 2003; 62: 350-352.
13. Gabriel SE, Sunku J, Salvarani C, O'Fallon WM, Hunder GG. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997; 40: 1873-1878.
14. Cantini F, Salvarani C, Olivieri I, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 2000; 30: 17-24.
15. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid induced osteoporosis. N Engl J Med 1998; 339: 292-299.
16. Nesher G, Sonnenblick M, Friedlander Y. Analysis of steroid related complications and mortality in temporal arteritis: a 15-years survey of 43 patients. J Rheumatol 1994; 21: 1283-1286.
17. Goodwin JS. Progress in gerontology: polymyalgia rheumatica and temporal arteritis. J Am Geriatr Soc 1992; 40: 515-525.
18. Evans JM, Hunder GG. Polymyalgia rheumatica and giant cell arteritis. Clin Geriatr Med 1998; 14: 455-473.
19. Helfgott SM, Kieval RI. Polymyalgia rheumatica in patients with a normal erythrocyte sedimentation rate. Arthritis Rheum 1996; 39: 304-307.
20. van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant-cell arteritis? Ann Rheum Dis 1996; 55: 218-223.
21. Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomised, double blind, placebo-controlled trial. Ann Intern Med 2001; 134: 106-114.
22. Ferraccioli GF, Di Poi E, Damato R. Steroid sparing therapeutic approaches to polymyalgia rheumatica giant cell arteritis. State of art and prospectives. Clin Exp Rheumatol 2000; 18 (Suppl 20): 58-60.
23. Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I. Treatment of longstanding Active Giant cell Arteritis with Infliximab: report of four cases. Arthritis Rheum 2001; 44: 2933-2935.
24. Cantini F, Niccoli L, Nannini C, et al. Long-term follow up of patients with refractory Giant cell arteritis (GCA) treated with Infliximab. Ann Rheum 2003; 62 (Suppl 1): 207 (Abstr.).
25. Salvarani C, Cantini F, Olivieri I, et al. Treatment of longstanding active polymyalgia rheumatica with infliximab: report of four cases. Ann Rheum 2002; 61 (Suppl 1): 214 (Abstr.).
26. Salvarani C, Cantini F, Niccoli L, et al. Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. J Rheumatol 2003; 30: 760-763.
27. Migliore A, Martin Martin SL, Valente C, et al. TNF alpha blockade induces clinical remission in patients with polymyalgia rheumatica associated with diabetes mellitus and/or osteoporosis. EULAR 2004, Ann Rheum Dis 2004; 63(S1): AB0206.
28. Straub RH, Gluck T, Cutolo M, et al. The adrenal steroid status in relation to inflammatory cytokines (IL6 and TNF) in polymyalgia rheumatica. Rheumatology 2000, 39: 624-631.
29. Buch MH, Conaghan PG, Quinn MA, et al. True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha? Ann Rheum Dis 2004; 63: 1344-1346.
30. Di Rocco P, Manco M, Rosa G, et al. Lowered tumor necrosis factor receptors, but not increased insulin sensitivity, with infliximab. Obes Res 2004; 12: 734-739.